Clinical Research Directory

Inclusion Criteria: * Symptomatic MM in the first line in patients who are not candidates for autologous bone marrow transplantation. * Patients eligible for one of the treatments considered as standard in a patient who is not eligible for autograft, according to ESMO's European recommendations * MM with measurable disease either by the serum evaluation of the monoclonal component or by the determination of free light chains (serum or urinary). * Patient affiliated with a social insurance scheme * The patient must understand and voluntarily sign the informed consent form * Women of childbearing potential must have a serum pregnancy test (performed within 2 days before each PET scan.) * Women of childbearing potential must use an effective contraceptive method throughout the course of the study and for 30 days after the last PET. * Male patients (vasectomised or not) with a pregnant partner or a partner of childbearing potential must use a condom and a spermicide until 90 days after the last PET. * HIV serology known to be negative * Karnofsky ≥ 70 or ECOG 0-1 Exclusion Criteria: * Age under 18 years * Pregnancy or breastfeeding * Male or female refusing birth control conditions * Primary AL amyloidosis and myeloma complicated by amyloidosis * Neutropenia \<1000 PN / mm3 * Thrombocytopenia \<70,000 / mm3 * Hepatic impairment: bilirubin\> 35μmol / L and SGOT, SGPT, alkaline phosphatase greater than 3 N * Renal impairment defined by creatinine clearance \<50 ml / min * History of other malignancies with the exception of basal cell carcinoma and stage I cervical cancer * Severe active infection * Active infection with known hepatitis B or C virus. * Patient with insulin-dependent or non-insulin-dependent diabetes mellitus. * Intolerance or known allergy to any of the study drugs or any of its analogues * Psychiatric illness that may interfere with participation in the study * Patient under safeguard of justice * Intellectual inability to sign informed consent * Persons protected by law